A “Future Cleantech Commons™ Tenant“, PKA SoftTouch Inc., has been awarded a “Top 10 Best Invention” award at the International Invention Innovation Competition in Canada (iCAN 2020) for their Micro-Needle Device.
The award was the only one made to a Canadian company, and the invention ranked second overall.
Disclosure: PKA SoftTouch is registered on our Cleantech Innovation Portal. You can join PKA on the portal by registering your cleantech innovation here.
The annual invention & innovation competition is organized by the Toronto International Society of Innovation & Advanced Skills (TISIAS) to allow both local and international participants to showcase their scientific research, new products, and technologies.
PKA’s “micro-needle” device will revolutionize the 16 billion syringe market, one that has not seen any significant technology developments in over 170 years.
“The purpose of our single-shot, pre-filled, pre-measured device is simple: to deliver a drug to the body of the patient effectively and painlessly,” PKA’s CEO and Co-founder, Dick Crawford, told us.
“Our revolutionary technology achieves this with every single application.”
About the size of a cork, PKA’s device, when properly applied to the skin of an animal or human, will result in a 95% to 97% delivery of the drug into the skin.
“Getting this global recognition here in Canada, is very rewarding,” says Crawford.
“Our fifteen years of development has brought us to the final stage of testing, and we hope to confirm our first licence in the next six months.”
About PKA SoftTouch
PKA SoftTouch Corp. is a leading-edge research and development company that has created a unique, revolutionary and proprietary device, the PKA SoftTouch Micro-Needle. The PKA SoftTouch Micro-Needle meets the need for humans and animals to administer lifesaving drugs in a painless, safe, inexpensive and simple manner. Patented worldwide, their pre-filled micro-needle technology is the only effective device that injects medication into the skin layers where there are no nerves and therefore no pain. Positioned to replace the traditional syringe delivery of drugs, PKA aims to enhance the quality of life for millions of users worldwide. PKASoftTouch is in its final days of financing on the FrontFundr platform and on-track to launch its final clinical trials. All Canadians can participate in the campaign at https://www.frontfundr.com/PKASoftTouch. Connect with PKA SoftTouch: Website | Facebook | LinkedIn | Instagram | Twitter
Contact: Dick Crawford | E: email@example.com | 705.652.1100